Entering text into the input field will update the search result below

Mersana Therapeutics GAAP EPS of -$0.61 misses by $0.60, revenue of $5.57M misses by $51.21M

Nov. 07, 2022 7:15 AM ETMersana Therapeutics, Inc. (MRSN) StockBy: Meghavi Singh, SA News Editor
  • Mersana Therapeutics press release (NASDAQ:MRSN): Q3 GAAP EPS of -$0.61 misses by $0.60.
  • Revenue of $5.57M (vs. $0.01M) misses by $51.21M.
  • Cash, cash equivalents and marketable securities as of September 30, 2022, were $290.1M, compared to cash and cash equivalents of $177.9M as of December 31, 2021. Mersana expects that its available funds will be sufficient to support its operating plan commitments into the first half of 2024.

Recommended For You

More Trending News

About MRSN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MRSN--
Mersana Therapeutics, Inc.